接受重组人促甲状腺素放射性碘治疗的患者中，(131)I 放射性会干扰甲状腺球蛋白的测量吗？
Does (131)I Radioactivity Interfere with Thyroglobulin Measurement in Patients Undergoing Radioactive Iodine Therapy with Recombinant Human TSH?
作者信息
Park Sohyun, Bang Ji-In, Lee Ho-Young, Kim Sang-Eun
机构信息
Department of Nuclear Medicine, Seoul National University Bundang Hospital, 173-82, Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 463-707 Republic of Korea ; Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea.
Department of Nuclear Medicine, Seoul National University Bundang Hospital, 173-82, Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 463-707 Republic of Korea ; Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea ; Laboratory of Molecular Imaging and Therapy of Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
出版信息
Nucl Med Mol Imaging. 2015 Jun;49(2):122-6. doi: 10.1007/s13139-014-0317-x. Epub 2015 Jan 27.
OBJECTIVES
Recombinant human thyroid-stimulating hormone (rhTSH) is widely used in radioactive iodine therapy (RIT) to avoid side effects caused by hypothyroidism during the therapy. Owing to RIT with rhTSH, serum thyroglobulin (Tg) is measured with high (131)I concentrations. It is of concern that the relatively high energy of (131)I could interfere with Tg measurement using the immunoradiometric assay (IRMA). We investigated the effect of (131)I administration on Tg measurement with IRMA after RIT.
METHODS
A total of 67 patients with thyroid cancer were analysed retrospectively. All patients had undergone rhTSH stimulation for RIT. The patients' sera were sampled 2 days after (131)I administration and divided into two portions: for Tg measurements on days 2 and 32 after (131)I administration. The count per minute (CPM) of whole serum (200 μl) was also measured at each time point. Student's paired t-test and Pearson's correlation analyses were performed for statistical analysis.
RESULTS
Serum Tg levels were significantly concordant between days 2 and 32, irrespective of the serum CPM. Subgroup analysis was performed by classification based on the (131)I dose. No difference was noted between the results of the two groups.
CONCLUSIONS
IRMA using (125)I did not show interference from (131)I in the serum of patients stimulated by rhTSH.
目的
重组人促甲状腺激素（rhTSH）广泛应用于放射性碘治疗（RIT），以避免治疗期间甲状腺功能减退引起的副作用。由于采用rhTSH进行RIT，血清甲状腺球蛋白（Tg）是在高浓度（131）I的情况下进行测量的。令人担忧的是，（131）I相对较高的能量可能会干扰使用免疫放射分析（IRMA）测量Tg。我们研究了RIT后给予（131）I对使用IRMA测量Tg的影响。
方法
回顾性分析了67例甲状腺癌患者。所有患者均接受了rhTSH刺激以进行RIT。在给予（131）I后2天采集患者血清，并分为两份：一份用于在给予（131）I后第2天和第32天测量Tg。在每个时间点还测量了全血清（200μl）的每分钟计数（CPM）。采用配对t检验和Pearson相关分析进行统计学分析。
结果
无论血清CPM如何，第2天和第32天的血清Tg水平均显著一致。根据（131）I剂量进行分类的亚组分析显示，两组结果之间没有差异。
结论
使用（125）I的IRMA在rhTSH刺激的患者血清中未显示出受（131）I的干扰。
Zotero 插件